Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| HSBC Holdings | 1.76% | $17.39M | £222.90B | 44.94% | 80 Outperform | |
| GlaxoSmithKline | 1.49% | $14.71M | £91.50B | 53.84% | 77 Outperform | |
| Novartis AG | 1.42% | $14.06M | CHF242.43B | 31.88% | 80 Outperform | |
| Murata Manufacturing Co | 1.18% | $11.72M | ¥6.66T | 40.19% | 77 Outperform | |
| Standard Chartered | 1.15% | $11.43M | £40.75B | 69.55% | 77 Outperform | |
| ING GROEP | 1.12% | $11.09M | €70.29B | 50.62% | 61 Neutral | |
| Barclays | 1.08% | $10.70M | £67.02B | 58.86% | 78 Outperform | |
| ArcelorMittal | 1.06% | $10.45M | €41.61B | 103.58% | 73 Outperform | |
| Roche Holding AG | 1.05% | $10.35M | CHF294.84B | 46.36% | 73 Outperform | |
| AstraZeneca | 1.04% | $10.27M | £240.98B | 32.79% | 80 Outperform |